Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases with unmet medical needs, has recently provided a shareholder update detailing its clinical and strategic milestones. The company’s President and CEO, Dr. Christopher J. Schaber, emphasized the importance of upcoming data readouts for its lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) in cutaneous T-cell lymphoma anticipated in the second half of 2026, and several updates in the third and fourth quarters of 2025 for its psoriasis (SGX302) and Behçet’s Disease (SGX945) treatments. An investigator-initiated study has already demonstrated a promising 75% success rate at 18 weeks.

The company projects significant financial potential for HyBryte(TM), with peak U.S. annual sales estimated to exceed $90 million and global opportunities surpassing $2 billion across its pipeline. With approximately $7 million in cash, Soligenix is actively exploring partnerships and mergers and acquisitions to extend its cash runway into the first quarter of 2026. This strategic financial management is aimed at preparing for global regulatory filings and the potential commercialization of its treatments.

Soligenix’s Specialized BioTherapeutics business segment is advancing towards the potential commercialization of HyBryte(TM), a novel photodynamic therapy for cutaneous T-cell lymphoma, with regulatory approvals sought worldwide following the successful completion of a second Phase 3 study. The company is also expanding its synthetic hypericin (SGX302) into psoriasis treatment and developing its first-in-class innate defense regulator technology, dusquetide (SGX942), for inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 for Behçet’s disease.

In addition to its Specialized BioTherapeutics segment, Soligenix’s Public Health Solutions business segment is focused on developing vaccines, including RiVax(R) for ricin toxin, filovirus vaccines for diseases like Marburg and Ebola, and CiVax(TM) for COVID-19 prevention. These programs leverage the company’s proprietary heat stabilization platform technology, ThermoVax(R), and have been supported by government grants and contracts from notable agencies such as the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.

This update from Soligenix Inc. underscores the company’s commitment to addressing rare diseases with significant unmet medical needs, highlighting the potential impact of its pipeline on patients and the healthcare market. The anticipated milestones and financial projections reflect the company’s strategic direction and its efforts to bring innovative treatments to market.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix Inc. Targets Key Milestones in Rare Disease Treatment Pipeline.